MX2013005801A - Assays and biomarkers for lrrk2. - Google Patents

Assays and biomarkers for lrrk2.

Info

Publication number
MX2013005801A
MX2013005801A MX2013005801A MX2013005801A MX2013005801A MX 2013005801 A MX2013005801 A MX 2013005801A MX 2013005801 A MX2013005801 A MX 2013005801A MX 2013005801 A MX2013005801 A MX 2013005801A MX 2013005801 A MX2013005801 A MX 2013005801A
Authority
MX
Mexico
Prior art keywords
lrrk2
biomarkers
assays
screening
parkinson
Prior art date
Application number
MX2013005801A
Other languages
Spanish (es)
Inventor
Daisy Bustos
Donald Kirkpatrick
Tracy Kleinheinz
John Moffat
Zejuan Sheng
Shuo Zhang
Haitao Zhu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US41820810P priority Critical
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to PCT/US2011/062468 priority patent/WO2012075046A1/en
Publication of MX2013005801A publication Critical patent/MX2013005801A/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2835Movement disorders, e.g. Parkinson, Huntington, Tourette
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment; Prognosis

Abstract

Biomarkers for screening subjects for Parkinson's disease and providing companion diagnostic tools for therapies using LRRK2 modulators, and assays for screening compounds and compositions for modulation of LRRK2 activity.
MX2013005801A 2010-11-30 2011-11-29 Assays and biomarkers for lrrk2. MX2013005801A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US41820810P true 2010-11-30 2010-11-30
PCT/US2011/062468 WO2012075046A1 (en) 2010-11-30 2011-11-29 Assays and biomarkers for lrrk2

Publications (1)

Publication Number Publication Date
MX2013005801A true MX2013005801A (en) 2013-07-17

Family

ID=45217723

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005801A MX2013005801A (en) 2010-11-30 2011-11-29 Assays and biomarkers for lrrk2.

Country Status (9)

Country Link
EP (1) EP2646819A1 (en)
JP (1) JP2014504362A (en)
KR (1) KR20130121903A (en)
CN (1) CN103348243A (en)
BR (1) BR112013013457A2 (en)
CA (1) CA2818428A1 (en)
MX (1) MX2013005801A (en)
RU (1) RU2013129818A (en)
WO (1) WO2012075046A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD20140130A2 (en) 2012-06-29 2015-04-30 Pfizer Inc. Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
WO2014059052A1 (en) * 2012-10-09 2014-04-17 Uab Research Foundation Methods and compositions for diagnosis and treatment of parkinson's disease and parkinsonism
US9582909B2 (en) * 2012-11-15 2017-02-28 Shimadzu Corporation Chromatograph mass spectrometry data processing device
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
CN108137586A (en) 2015-09-14 2018-06-08 辉瑞大药厂 As novel imidazo [4,5-c] quinoline of LRRK2 inhibitor and imidazo [4,5-c] [1,5] 7-naphthyridine derivatives
CN105331721A (en) * 2015-11-27 2016-02-17 首都医科大学宣武医院 Method, primers and kit for detecting PD (Parkinsons Disease) pathogenic gene mutation
EP3472153A1 (en) 2016-06-16 2019-04-24 Denali Therapeutics Inc. Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2009101384A (en) 2006-06-20 2010-07-27 Новартис АГ (CH) Alzheimer's disease progress biomarkers
WO2008091799A2 (en) * 2007-01-22 2008-07-31 The Trustees Of Columbia University In The City Of New York Cell-based methods for identifying inhibitors of parkinson's disease-associated lrrk2 mutants
GB0706709D0 (en) * 2007-04-05 2007-05-16 Medical Res Council Methods
US20100175140A1 (en) * 2008-12-19 2010-07-08 The Johns Hopkins University Leucine-rich repeat kinase (LRRK2) drosophila model for parkinson's disease: wildtype1 (WT1) and G2019S mutant flies
CA2760794C (en) * 2009-05-05 2017-07-25 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
US8367349B2 (en) * 2010-04-19 2013-02-05 Medical Research Council Methods for identifying modulators of LRRK2

Also Published As

Publication number Publication date
RU2013129818A (en) 2015-01-10
EP2646819A1 (en) 2013-10-09
CN103348243A (en) 2013-10-09
BR112013013457A2 (en) 2017-07-11
WO2012075046A9 (en) 2012-09-13
KR20130121903A (en) 2013-11-06
CA2818428A1 (en) 2012-06-07
JP2014504362A (en) 2014-02-20
WO2012075046A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
IL265397D0 (en) Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
PH12017502300A1 (en) Pesticidal compositions and processes related thereto
HRP20171660T1 (en) Compounds and methods for kinase modulation, and indications therefor
HK1209315A1 (en) Glycerophospholipids for the improvement of cognitive functions
HK1201274A1 (en) 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof 33- 19-
PH12016501389B1 (en) S1p modulating agents
UA117362C2 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MX362004B (en) Pyrrolobenzodiazepines and conjugates thereof.
WO2013122932A4 (en) Topical use of a skin-commensal prebiotic agent and compositions containing the same
IL229114D0 (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
NZ711896A (en) Compounds and methods for kinase modulation, and indications therefor
PH12013502230A1 (en) Multispecific antibodies
AU2013361107A8 (en) Human anti-tau antibodies
MX2019008212A (en) Fibrous structures comprising particles and methods for making same.
WO2013033627A3 (en) Diagnosis and treatment of arthritis using epigenetics
PH12014501976B1 (en) Toner, developer, and color toner set
GB2509668A (en) Bone fixation system with opposed mounting portions
IL228701D0 (en) Bcma-based stratification and therapy for multiple myeloma patients
MX2014012578A (en) Cd3 binding polypeptides.
CO6781536A2 (en) FGFR1 agonists and methods of use
MX2013005065A (en) Pesticidal compositions and processes related thereto.
MX2015001601A (en) Methods of treating a tauopathy.
WO2012082436A3 (en) Modulators of histone methyltransferase, and methods of use thereof
HK1219491A1 (en) Modulators of myc, methods of using the same and methods of identifying agents that modulate myc myc myc
AU2012245309C1 (en) Antibody polypeptides that antagonize CD40